ProCE Banner Activity

New Treatments for the Prevention of Migraine

Clinical Thought
My take on real-world successes, challenges, and ongoing questions on the use of monoclonal antibodies that target CGRP for migraine prophylaxis.

Released: April 09, 2020

Expiration: April 08, 2021

No longer available for credit.

Share

Faculty

Jessica Ailani

Jessica Ailani, MD

Director
MedStar Georgetown Headache Center
Professor of Clinical Neurology
Department of Neurology
MedStar Georgetown University Hospital
Washington, DC

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Allergan

Amgen, Inc.

Lundbeck

Faculty Disclosure

Primary Author

Jessica Ailani, MD

Director
MedStar Georgetown Headache Center
Professor of Clinical Neurology
Department of Neurology
MedStar Georgetown University Hospital
Washington, DC

Jessica Ailani, MD, has disclosed that she has received consulting fees from Allergan, Amgen, Biohaven, Health Monitor, Impel, Lilly, Lundbeck, Neurodiem, Revance, Satsuma, Teva, Theranica, and Zosano; funds for research support paid to her institution from Allergan, American Migraine Foundation, Biohaven, Lilly, and Zosano; and fees for non-CME/CE services from Allergan, Amgen, Biohaven, Lilly, Lundbeck, and Teva.